Literature DB >> 18696184

Sperm cryopreservation in patients with hematologic malignancies.

Akiko Meguro1, Kazuo Muroi2, Takuji Miyoshi3, Tomohiro Matsuyama1, Masaki Mori1, Tadashi Nagai1, Keiya Ozawa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18696184     DOI： 10.1007/s12185-008-0149-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  17 in total

1.  Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

Authors:  A Reiter; M Schrappe; W D Ludwig; M Tiemann; R Parwaresch; M Zimmermann; E Schirg; G Henze; G Schellong; H Gadner; H Riehm
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

2.  Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.

Authors:  P Lemez; V Urbánek
Journal:  Neoplasma       Date:  2005       Impact factor: 2.575

3.  Autologous gamete cryopreservation before hemopoietic stem cell transplantation.

Authors:  Takahiro Nagashima; Kazuo Muroi; Chizuru Kawano-Yamamoto; Takuji Miyoshi; Ken Ohmine; Masaki Toshima; Akira Miyazato; Masaaki Takatoku; Tadashi Nagai; Masaki Mori; Norio Komatsu; Keiya Ozawa
Journal:  Med Sci Monit       Date:  2005-03

4.  Semen quality before and after gonadotoxic treatment.

Authors:  G Bahadur; O Ozturk; A Muneer; R Wafa; A Ashraf; N Jaman; S Patel; A W Oyede; D J Ralph
Journal:  Hum Reprod       Date:  2005-02-02       Impact factor: 6.918

Review 5.  Treatment options for the infertile male with cancer.

Authors:  David Shin; Kirk C Lo; Larry I Lipshultz
Journal:  J Natl Cancer Inst Monogr       Date:  2005

6.  Late effects of treatment in survivors of childhood acute myeloid leukemia.

Authors:  W Leung; M M Hudson; D K Strickland; S Phipps; D K Srivastava; R C Ribeiro; J E Rubnitz; J T Sandlund; L E Kun; L C Bowman; B I Razzouk; P Mathew; P Shearer; W E Evans; C H Pui
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

Review 7.  Assisted reproductive technologies and the risk of birth defects--a systematic review.

Authors:  Michèle Hansen; Carol Bower; Elizabeth Milne; Nicholas de Klerk; Jennifer J Kurinczuk
Journal:  Hum Reprod       Date:  2004-11-26       Impact factor: 6.918

8.  Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease.

Authors:  M L Meistrich; G Wilson; K Mathur; L M Fuller; M A Rodriguez; P McLaughlin; J E Romaguera; F F Cabanillas; C S Ha; L I Lipshultz; F B Hagemeister
Journal:  J Clin Oncol       Date:  1997-12       Impact factor: 44.544

9.  Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute.

Authors:  Miyuki Akutsu; Saburo Tsunoda; Tohru Izumi; Masaru Tanaka; Susumu Katano; Koichi Inoue; Seiji Igarashi; Kaoru Hirabayashi; Yusuke Furukawa; Ken Ohmine; Kazuya Sato; Hiroyuki Kobayashi; Keiya Ozawa; Keita Kirito; Takahiro Nagashima; Satoshi Teramukai; Masanori Fukushima; Yasuhiko Kano
Journal:  Oncol Res       Date:  2008       Impact factor: 5.574

10.  Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  Marleen A E van der Kaaij; Natacha Heutte; Nolwenn Le Stang; John M M Raemaekers; Arnold H M Simons; Patrice Carde; Evert M Noordijk; Christophe Fermé; José Thomas; Houchingue Eghbali; Hanneke C Kluin-Nelemans; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2007-05-21       Impact factor: 44.544
View more
  1 in total

Review 1.  Evaluation of the azoospermic male.

Authors:  Robert Oates
Journal:  Asian J Androl       Date:  2011-12-19       Impact factor: 3.285
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.